The Patent Expiration Of Dacogen Is Now A Non Issue. No Generic Mfg Will Compete Against The New Standard Of Care.
The oral delivery of a low dose for sustained circulation in the body. "Relevant animal studies revealed that the product can result in therapeutic exposures of decitabine at low doses. The profile of E7727 is
expected to result in low inter-patient variability across doses of decitabine
with little or no gastrointestinal safety issues."
Sorry you are short ASTX . You never wondered why Astx didn't bother to extend the patent on Dacogen? With SGI-110 and E7727 and the partnership with two great drug companies WITH distribution networks globally they will be the only life saving game in town. Approval will come much quicker than you predict... Remember this is not ASTX'S and their partners only drug in development.
I agree, free. Although, I doubt the FDA would approve any accelerated path on this one. It is probably too radical a varience from the traditional method of delivery. Expect a full battery of trials. Your 6 year assessment is likely to be accurate, and there could be a lot of hurdles along the way to sidetrack or kill this one. We should not get too excited yet.